15723-90-7

Usage

Uses

Used in Pharmaceutical Industry:
4-Nitrobenzamidine, Hydrochloride is used as a synthetic intermediate for the preparation of labelled Diminazene (D479550), which is a medication used to treat certain conditions. Its role in the synthesis process is crucial for the development of this pharmaceutical compound.
Used in Organic Synthesis:
In the field of organic chemistry, 4-Nitrobenzamidine, Hydrochloride serves as a valuable compound for various synthetic applications. Its unique chemical properties allow it to be used in the creation of different organic compounds, contributing to the advancement of chemical research and development.

InChI:InChI=1/C7H7N3O2.ClH/c8-7(9)5-1-3-6(4-2-5)10(11)12;/h1-4H,(H3,8,9);1H

Upstream product

• 619-72-7 4-nitrobenzonitrile 
• 40546-45-0 ethyl 4-nitrobenzenecarboximidoate hydrochloride 
• 555-16-8 4-nitrobenzaldehdye 
• 52708-02-8 4-nitrobenzimidic acid methyl ester 

Downstream Products

• 3858-83-1 p-aminobenzamidine 
• 91272-20-7 2-(p-nitrophenyl)-5,6-pentamethylenepyrimidin-4(3H)-one 
• 110700-77-1 6-Chloromethyl-2-(4-nitro-phenyl)-1H-pyrimidin-4-one 
• 125772-54-5 4-nitrobenzamidinium acetate 
• 125772-68-1 4-nitrobenzamidinium pyruvate 
• 95222-73-4 2,4-bis-(4-nitro-phenyl)-6-phenyl-pyrimidine 
• 2498-50-2 4-aminobenzamidine monohydrochloride 
• 783364-26-1 3-(2-(4-nitrophenyl)-1H-imidazol-5-yl)benzonitrile 
• 88541-07-5 5-Chloro-3-(4-nitro-phenyl)-1,2,4-thiadiazole 
• 1106994-63-1 C₂₂H₁₄N₄O₄ 
• 1638156-57-6 4-ethynyl-5-(4-methylphenyl)-2-(4-nitrophenyl)pyrimidine 
• 13866-12-1 4-nitro-N-(2-oxo-2-phenylacetyl)benzamide 

Relevant academic research and scientific papers

Synthesis and biophysical testing of a novel pyrrole-containing polyamide-benzamidine hybrid

This communication details the rationale for the design of a novel polyamide molecule, 1, in which the standard dimethylamino C-terminus functionality has been replaced with a benzamidine moiety. The synthesis of this molecule and the subsequent DNA binding properties, determined from surface plasmon resonance and DNA melts are reported. The benzamidine moiety was shown to significantly increase the binding affinity of the polyamide to its cognate AATTT sequence compared to the parent C-terminus compound 2.

α-Amino acid-derived 2-phenylimidazoles with potential antimycobacterial activity

α-Amino acid-derived 2-phenylimidazole derivatives were designed, synthesized, and further investigated as potential antimycobacterial agents. The synthesis of target imidazole derivatives involved the transformation of Cbz-protected α-amino acids (Ala, Val, Phe, Leu, iLe, and Pro) into α-diazoketones and α-bromoketones, respectively. Subsequent treatment of α-bromoketones with (4-nitro) benzamidine afforded imidazole derivatives bearing α-amino acid residue appended to the imidazole C4 and (4-nitro)phenyl ring in the position C2. Antimycobacterial activities of both series of compounds against M. tuberculosis, M. avium, and M. kansasii were screened and basic structure-activity relationships were further evaluated.

Design, synthesis and biological evaluation of novel 2-phenyl pyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors

BTK is an effective target for the treatment of B-cell malignant tumors and autoimmune diseases. In this work, a series of 2-phenyl pyrimidine derivatives were prepared and their preliminary in vitro activities on B-cell leukemia cells as well as the BTK enzyme were determined. The results showed that compound 11g displayed the best inhibitory activity on BTK with an inhibition rate of 82.76% at 100 nM and excellent anti-proliferation activity on three B-cell leukemia lines (IC50 = 3.66 μM, 6.98 μM, and 5.39 μM against HL60, Raji and Ramos, respectively). Besides, the flow cytometry analysis results indicated that 11g inhibited the proliferation of the Raji cells in a dose- and time-dependent manner, and blocked the Ramos cells at the G0/G1 phase, which is in accordance with the positive control ibrutinib. The mechanism investigation demonstrated that 11g could inhibit the phosphorylation of BTK and its downstream substrate phospholipase γ2 (PLCγ2). All these results showed that 11g was a promising lead compound that merited further optimization as a novel class of BTK inhibitor for the treatment of B-cell lymphoblastic leukemia.

2-phenylpyrimidine compounds, preparation method and medical application

The invention belongs to the field of medicines and particularly relates to 2-phenylpyrimidine compounds and pharmacologically-acceptable salts thereof and an isotope marker. The invention also discloses a pharmaceutical composition containing the substances and application of the pharmaceutical composition for treating diseases related with protein kinase activity, such as cancer and inflammation. (The formula is shown in the description).

Bispyrimidine diamine and preparation method thereof

The invention discloses bispyrimidine diamine and a preparation method thereof. According to the preparation method, the bispyrimidine diamine is prepared through a five-step reaction by taking nitrobenzonitrile as a raw material. The bispyrimidine diamine disclosed by the invention can also be used as a raw material for synthesising high-performance polymers, such as polyimide and polyamide, and has a wide application prospect in the aspect of high-performance fibres.

Transition-metal-free approach to 4-ethynylpyrimidines via alkenynones

A practical approach to the synthesis of 4-ethynylpyrimidines by the condensation of arylamidines with 2-aryl-1-ethoxy-5-(trimethylsilyl)pent-1-en-4- yn-3-ones has been developed. As these latter ketones are easily accessible from bis(trimethylsilyl)acetylene and arylacetyl chlorides, the regioselective condensation reported herein provides a facile access to both TMS-protected and unprotected 4-ethynylpyrimidines in yields of up to 85%. Copyright

Synthesis and structure of aroylamidines and N-arylbenzamidines hydrochlorides

Aroylamidines can be obtained as salts in a reaction of the corresponding arylcarbonitriles with anhydrous ethanol in the presence of dry HCl followed by treating intermediate imidoesters with alcoholic solution of ammonia. N-Arylbenzamidines are obtained by reacting benzonitrile with arylamines in the presence of AlCl3. The structure of arylamines and the reaction conditions signifi cantly affect the yield of the target product, and sometimes the very possibility of its preparation. Pleiades Publishing, Ltd., 2012.

PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

The invention relates to pyrimidine compounds of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

SUBSTITUTED IMIDAZOTRIAZINES

The invention relates to novel substituted imidazotriazines, to methods for the production thereof, and to their use for producing medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative diseases, particularly Parkinson's disease and schizophrenia.

IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS

The preferred embodiments are directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. The preferred embodiments also relate to imidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents. The preferred embodiments further relate to small molecules which suppress cytokines and leukocytes.